Anu
Muona is a founder and CEO of Aranda. Anu has over 10 years of
experience in preclinical drug development in small molecules for various
target indications. Prior founding Aranda she has served as a Head of Cellular
and Molecular Biology at Medeia Therapeutics Ltd, the originator of ADA-308
program, her major responsibility being the pharmacological development of the
program. She has also been a member of a team exploring the potential of bone
marrow stem cell-based therapy for the treatment of Alzheimer’s disease at
Medeia. Anu has a strong scientific background in molecular biology and
genetics. She received her PhD in molecular biology in the Collagen research
unit of University of Oulu, Finland. She has completed extensive postdoctoral
training in stem cell research and its applications in neurodegenerative
diseases at the University of Eastern Finland, Kuopio.
